Fabrus

Fabrus identifies and develops functional therapeutic monoclonal antibodies targeting challenging cell surface targets such as GPCRs and ion channels. The company has assembled an experienced scientific team, which has reached and exceeded its milestones by establishing a unique antibody discovery platform and identifying multiple preclinical candidates against significant cancer targets.